biospace med, an orthopaedic imaging company with headquarters in Paris and Atlanta, has secured $18 million in new financing.
NBGI Ventures in London and a trio of French firms led the financing.
biospace med has developed what it calls an “ultra low dose” means of delivering 2D and 3D xrays. The firm will use the new funding to expand worldwide marketing of its technology called EOS.
“This is a quantum leap in technology for the orthopaedic and imaging communities, which have been waiting for a solution to address their specific needs,” said Marie Meynadier, biospace med’s chief executive officer.
“This new round of financing will accelerate the worldwide commercial deployment of EOS, which already is installed in several European countries and Canada. With the recent FDA approval to market EOS in the United States, this financing package will accelerate our market penetration there as well.”
EOS is able to deliver a whole or partial body image with one scan and with up to 10 times a reduction in radiation compared to other Xray systems.